Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by barcodewhizon Dec 09, 2004 3:16pm
148 Views
Post# 8292671

RE: selling shares $$$$$$

RE: selling shares $$$$$$ well said... sounds like we're on the same program except for I HELD MY NOSE and bought the dip... couldnt help myself... so far so good. Despite the improvements in IR, I still think the company can do ALOT to get more exposure in terms of their core competencies... There's still a HUGE GAP in my opinion in terms of what the company has proven it can do and what the market thinks they can do with their technology. Specifically, I think they could have done ALOT more in terms of educating the market on what their Prion removal technology can do and what it means to the world. Pall is a good example. Despite having inferior technology ( by industry accounts and as per THE LANCET ) They have been effectively getting the word out that they have a solution. You would think they would have similar sensitivities as PROMETIC... IR hates hearing this because they say it compromises ongoing negotiations etc and confidentiality issues... Obviously the ARC relationship makes the situation particularly sensitive for PLI because we are talking about public perception of blood safety and all the related implications....But there comes a point where theres a balance between SILENCE and SENSATIONLISM... my opinion is they have erred on the side of SILENCE and up til now its been quite damaging. I do hope that changes... It will go along way to building fundamental value and confidence.
Bullboard Posts